Effectiveness of atorvastatin in reducing inflammatory markers and hospitalization period in adults with COVID-19: a randomized clinical trial
Qom University of Medical Sciences Journal
; 16(9):744-755, 2022.
Article
in Persian
| CAB Abstracts | ID: covidwho-2319710
ABSTRACT
Background and Objectives:
Statins, which are primarily used for controlling blood cholesterol levels, have a well-known role in inhibiting the inflammatory process and reducing mortality rate of infectious diseases. This study aims to evaluate the effect of atorvastatin along with standard treatment protocol in hospitalized adults with COVID-19.Methods:
This randomized controlled clinical trial was conducted on adults hospitalized due to COVID-19 infection at Shahid Beheshti Hospital in Qom, Iran from April to September 2020. They were randomly divided into groups of treatment (n=37, receiving atorvastatin 40 mg daily for 30 days plus standard treatment protocol) and control (n=37, receiving standard treatment protocol alone). The data were analyzed in SPSS v.22 software using chi-square, paired t-test, and ANOVA. P < 0.05 was statistically significant.Results:
The CRP level in the atorvastatin-treated group decreased significantly such that there was a significant difference between the two groups after 30 days (P=0.01). There was no significant difference in Spo2 level on the discharge day. The length of hospitalization in the atorvastatin-treated group was significantly reduced compared to the control group (P < 0.05).Conclusion:
The use of atorvastatin as an adjunctive treatment method, can significantly reduce the length of hospitalization and CRP level after 30 days in hospitalized patients.
Prion; Viral; Bacterial and Fungal Pathogens of Humans [VV210]; Pharmacology [VV730]; Health Services [UU350]; human diseases; randomized controlled trials; atorvastatin; viral diseases; coronavirus disease 2019; adults; inflammation; biochemical markers; disease markers; hospitals; hospital admission; cholesterol; clinical trials; man; Severe acute respiratory syndrome coronavirus 2; Iran; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; high Human Development Index countries; lower-middle income countries; Middle East; West Asia; Asia; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; SARS-CoV-2; viral infections; biomarkers
Full text:
Available
Collection:
Databases of international organizations
Database:
CAB Abstracts
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Language:
Persian
Journal:
Qom University of Medical Sciences Journal
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS